We identified the first insertion mutation that specifies an apolipoprotein (apo)B truncation, apoB-70.5, in a father and son with hypobetalipoproteinemia (total and lowdensity lipoprotein [LDL] cholesterol <5th percentile, plasma apoB levels approximately one third of normal). The mutation is due to insertion of an adenine (A) into a 7-A repeat between cDNA position 9754 and 9760 of the apoB gene, resulting in a frame shift of 13 new amino acids and a termination codon at amino acid residue 3197. The DNA mutation cosegregated with the apoB truncation and hypobetalipoproteinemia in the kindred. The two apoB-70_5/apoB-100 heterozygotes also are apoE2 homozygotes by genotyping; /3-very-low-density lipoprotein (VLDL) was present, and VLDL cholesterol/trigh/ceride ratios were increased (0.29) in the plasmas of both. Density gradient ultracentrifugation and gel filtration chromatography profiles showed increased amounts of particles in the F amilial hypobetalipoproteinemia (FHBL) is characterized by plasma total and low-density lipoprotein (LDL) cholesterol concentrations below the 5th percentile (<3.9 mmol/L). Truncation specifying mutations of the apolipoprotein (apo)B gene account for a minority of these cases.
sible for their clearance by the LDL receptor and the putative chylomicron remnant receptor, respectively. Many genetic variants of apoE exist in the general population. 8 The apoE3 isoform is the most common and is defined as the wild type. ApoE4 is associated with increased LDL receptor binding and, on average, apoE4 homozygotes have higher than average total and LDL cholesterol levels, probably due to downregulation of their LDL receptors. ApoE2 displays severely reduced LDL and remnant receptor binding, and on average apoE2 homozygotes have low total and LDL cholesterol levels, probably due to upregulation of LDL receptors. 9 ' 10 Despite lower than average total cholesterol levels, plasmas of apoE2 homozygotes contain /3-migrating VLDL particles, representing chylomicron and VLDL remnants referred to as dysbetalipoproteinemia. Type III hyperlipidemia is also characterized as dysbetalipoproteinemia, but in addition, these patients have grossly elevated levels of both total cholesterol and triglycerides. More than 90% of type III hyperlipidemic individuals have the recessive form of the disease, that is, they are homozygous for the el allele. The apoE2/E2 phenotype occurs in 1% of the population, but while all apoE2/E2 subjects have dysbetalipoproteinemia, only 1 in 200 apoE2 homozygotes are hyperlipidemic, suggesting that additional genetic and/or environmental factors are needed for the full expression of the hyperlipidemic type III phenotype. 8 A dominant form of type III hyperlipidemia also exists, accompanied by rarer apoE mutations.
In this report we describe a rare insertion mutation of apoB leading to a new truncation, apoB-70.5, detectable in plasma. The two affected subjects are also apoE2 homozygotes. This unique situation allowed us to examine the effects of two independent gene variants (in the apoB and apoE genes) on the metabolism of apoB-containing particles, which has not been described before.
Methods

Blood Collection and Plasma Analyses
The proband was identified through screening of individuals with a total plasma cholesterol level <3.9 mmol/L. 12 Blood from fasted donors was drawn into tubes containing EDTA (3.0 mmol/L). Aliquots of blood were stored at -70°C for subsequent isolation of genomic DNA 13 or leukocytes were immediately isolated from packed blood cells using Histopaque-1077 (Sigma), and DNA was isolated. 1 * The blood remaining was centrifuged, aprotinin was added to the plasma (final concentration, 100 KIU/mL), and aliquots were stored at -70°C for immunoblotting (see below). Total plasma lipids and lipoprotein lipids were determined in the Washington University Lipid Research Center Core Laboratory using commercial kits (Technicon Instruments) and protocols of the Lipid Research Clinics. 13 Lipoprotein (Lp)(a) concentrations were determined by ELISA using a commercial kit (Terumo). Two aliquots of 1.5 mL and 14 mL of fresh plasma were used for fast protein liquid chromatography (FPLC) (Pharmacia) 16 and density gradient ultracentrifugation (DGUC), 17 respectively. ApoB and apoAI plasma concentrations were determined by immunonephelometry (Behring). ApoE genotyping was by a polymerase chain reaction (PCR)-based assay. 18 Identification of truncated forms of apoB in plasma by electrophoresis and immunoblotting was performed as previously described.
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Comparison Control Subjects
The lipoproteins of the two apoB-70.5 truncation apoE2/E2 genotype subjects were compared with those of three comparison control subjects. The first is a patient of the Lipid Research Clinic with apoE2/E2 phenotype and genotype and type III hyperlipidemia. Under treatment with Lopid (600 mg BID), his total plasma cholesterol and triglyceride concentrations were normal. The second control, an apoB-75/apoB-100 heterozygote (the proband in Reference 2), had an apoE3/E4 genotype. These individuals will be referred to as the apoE2/E2 control subjects and the apoB-75 control subjects. Finally, a normolipidemic subject (apoB-100/apoB-100 and apoE3/E3) was used in some studies as indicated.
PCR and DNA Sequencing
Two PCR primers encompassing a 1117-bp region of the apoB gene predicted to contain the mutation were synthesized by the Protein Chemistry Core Facility at the Washington University School of Medicine. The forward primer, apoB-70.5-1, started at cDNA position 9594 (5'-ACAGGCT-TGAAGGAATTCTTG-3') and the reverse primer, apoB-70.5-2, was complementary to the cDNA sequence between positions 10691 and 10710 (5'-ACCGTGTGCTCTTG-GAATTC-3') (see Knott et al 21 ) . One microgram of genomic DNA of the proband (I-l) and his son (II-4) and 50 pmol of each forward and reverse primer were amplified in 5xl00-/iL reactions with recombinant Taq polymerase. 22 The DNA was denatured at 94°C for 4 minutes, and 30 cycles of PCR at 92°C for 1 minute and 58°C for 5 minutes were performed in an automated temperature cycler (CoyTempCycler). Finally, a cycle at 55°C for 2 minutes and 72°C for 7 minutes was performed to complete polymerization of any unfinished PCR products. PCR products were purified by electrophoresis on a 2.5% Nusieve GTG gel (FMC Bioproducts), and aliquots of the ingel-PCR product were ligated directly into pGEM-T vector (Promega) according to the protocol supplied by FMC Bioproducts. Escherichia coli JM 109 were transformed with the recombinant plasmid. Clones were expanded, and clones containing the correct insert (identified by digesting with EcoRI) were sequenced by the Sequenase dideoxy sequencing procedure (United States Biochemical Corp). 23 Primers throughout the cloned apoB region were used to sequence overlapping regions of the entire cloned fragment. The mutation was detected when the forward primer apoB-70.5-1 was used for sequencing.
Allele-Specific Oligonucleotide Analyses for the ApoB-70.5 Mutation
A pair of allele-specific oligonucleotides (ASO) was synthesized with the following sequences: apoB-70.5-wt: 5'-CATTT-TGAAAAAAACAGAAA-3' and apoB-70.5-mt: 5'-CATTTTGAAAAAAAACAGAA-3'. The ASO assay was performed as described. 
3'-VNTR Analysis
The polymorphic region in the 3' untranslated region of the apoB gene was amplified by PCR as described by Boerwinkle et al. 24 Alleles were assigned by comparison with known alleles, kindly provided by Dr Lawrence Chan.
Primer Extension Assay
Plasmids containing the wild-type apoB sequence, generated as described in "PCR and DNA Sequencing," were used as templates. Oligonucleotide apoB-70.5-1 (see above) was end-labeled with y-^-ATP (Amersham International) and used as the primer. Two micrograms of plasmid DNA was denatured in 0.2 mol/L NaOH-0.2 mmol/L EDTA. The primer extension reactions were carried out at 37°C with either Sequenase version 2.0 (United States Biochemical Corp) in the presence of 6 mmol/L DTT and 0.2 mmol/L of each dNTP (dATP, dGTP, dTTP, dCTP) or AmpliTa^ (Perkin Elmer Cetus) in the presence of 33 mmol/L of each dNTP. At the indicated times, equal aliquots of the reaction mix were diluted 1.6 x in 95% formamide-2 mmol/L EDTA to stop the reaction, heated at 80°C, and separated on a 6% sequencing gel. A sequencing reaction of the same wild-type apoB template was run alongside the samples as a marker.
Agarose Gel Electrophoresis of Plasma and VLDL Fractions
Total VLDL (d< 1.066 g/mL) and subfractions VLDL1 (Sf >120), VLDL2 (Sf 60-120), and VLDL3 (Sf 20-60) were obtained by ultracentrifugation of plasma in a salt gradient formed in an SW 40 swinging bucket rotor. 25 Aprotinin was again added to each of the subfractions to 100 KIU/mL. Agarose gel electrophoresis was for 1.5 hours at 40 mA followed by 35 minutes at 50 mA. 26 The gel was fixed in 10% acetic acid, dried, and stained for lipids with Sudan black.
Composition Analysis of Total VLDL
Total VLDLs were analyzed for triglyceride, cholesterol ester, free cholesterol, and phospholipid using commercial kits (Wako Pure Chemicals). Apolipoproteins were quantified by separating 50 mg of total VLDL protein on a 3% to 25% SDS-PAGE gel followed by Coomassie blue staining. The bands for apoE, apoCs, apoB-100, apoB-48, and the truncated apoBs (when present) were scanned in a laser densitometer (LKB 2202 Ultrascan). The areas under the peaks used to calculate the various ratios were determined by Sigmascan (Jandel Scientific). BMI indicates body mass index; TChol, total plasma cholesterol; TG, total plasma triglyceride; VLDL-C, very-low-density llpoprotein cholesterol; VLDL-TG, VLDL triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; and VLDL C/TG, ratio of VLDL cholesterol and total triglycerides. Plasma lipid profiles were determined using protocols of the LJpkJ Research Clinics. Plasma apolipoprotein (apo) B and apoAl concentrations and apoE genotypes were determined as described in "Methods." ApoB phenotypes were assigned on the basis of Western blot analysis.
DGUC and Gel Permeation Chromatography (FPLC) of Plasma
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1.210 to 1.006 g/mL) in 40-mL Quickseal tubes (Beckman Instruments), and the gradient was centrifuged for 24 hours at 45 000 rpm at 12°C. 15 For chromatography, 1.5 mL of plasma was separated on the FPLC system. 16 -17 DGUC and FPLC fractions were analyzed for cholesterol and triglycerides (Wako Pure Chemicals), and other aliquots were electrophoresed on 3% to 6% SDS-PAGE gels and immunoblotted using the monoclonal anti-apoB antibody C1.4.
17 ApoB-100, apoB-70.5, or apoB-75 bands on the resulting autoradiographs were scanned, and areas under the peaks were determined as above. Areas corresponding to either apoB-100 or truncated apoB were summed. The areas determined for apoB-100 or the truncated apoB in any particular elution fraction were divided by the values representing the respective total densitometric areas to generate the distribution curves for each apoB species.
Results
The Proband and His Kindred
The proband (1-1) and his son (II-4) had plasma total and LDL cholesterol levels <5th percentile for their age, race, and sex (Table 1 and Fig 1) and plasma apoB concentrations that were =30% of unaffected kindred members. Lp(a) concentrations in both were =1 mg/dL. The proband's wife (1-2) and daughter (II-l) both had normal lipid profiles. Immunoblots of plasma from the proband and individuals with the previously identified apoB-31, 27 apoB-38.9, 17 apoB-37, 28 apoB-54.8, 12 apoB-75, 2 apoB-89, 29 and apoB-89/apoB-40 29 are shown in Fig 2. (The apoB-100/apoB-40 individual was identified in a kindred not known to be related to the one reported in Reference 29 but carries the identical mutation for apoB-40; E. Krul, W.A. Groenewegen, and G. Schonfeld, unpublished observations). Two bands are present in the proband's (1-1) plasma, apoB-100 and a new band with an estimated molecular weight of 382 kD (=B-69.5). This novel protein band was also present in the plasma of the proband's son (II-4) but not in the plasmas of the proband's wife (1-2) or their daughter (II-l) (results not shown).
The ApoB-70.5 Mutation
The 1117-bp region of the proband's apoB gene, which includes the site of the apoB-75 mutation, 2 was cloned into pGEM-T. Initially, the region from cDNA position 10069 to 10372, that is, immediately 5' to and including the apoB-75 mutation site at cDNA position 10366, was sequenced, but only the wild-type sequence 21 was found, thereby eliminating the apoB-75 mutation as the cause of the truncation. Next, oligonucleotide apoB-70.5-1 was used as a sequencing primer. Of the 10 clones sequenced, Plasma from the proband (1-1) and previously Identified truncations (see text) were electrophoresed on a 3% to 6% SDS-PAQE gel and immunoblotted with the C1.4 anti-apoB monoclonal antibody. Upoprotein(a) was preabsorbed from these samples. The lane labeled MARKER was plasma Immunopreclpttated with anti-apoB arrtiserum from an apoB-89/apoB-40 individual.
5 clones contained an insertion of an adenine (A) residue into a sequence containing 7 consecutive A's between cDNA position 9754 and 9760 inclusive (Fig 3) , and the rest contained the wild-type sequence. The gap between the apoB-75 mutation site and the insertion mutation was completely sequenced using multiple clones, and no Asn other sequence changes were found. The proband's son (II-4) had the same insertion mutation by DNA sequencing. Of 10 clones sequenced, 6 had the 8-A sequence and 4 had 7 A's (son's data not shown). The mutant sequence of 8 consecutive A's lead to a frame shift, the translation of 13 new amino acids (Lys-Gln-Lys-Gln-Cys-Ile-ArgPhe-Cys-His-Gln-Ile-Leu), and a termination codon at residue 3197, which is 70.5% of the full-length protein, consistent with the size of the new truncation on SDS gels (Fig 2) . Furthermore, to confirm the cosegregation in the kindred of the insertion mutation with the protein defect and hypobetalipoproteinemia, an ASO assay was performed. Both the mutant and the wild-type ASO bound to the DNA of the proband (1-1) and his affected son (H-4), whereas only the wild-type ASO bound to DNA from the proband's affected wife (1-2) and daughter (II-l) (not shown). In addition, the 3'-VNTR alleles of the apoB gene were determined. The paternal 3'-£37 allele was associated with the mutated apoB allele (Fig 1) .
Primer Extension Analysis of the ApoB-70.5 Mutation Site
Primer misalignment on repeat sequences is a proposed mechanism for generating small insertion or deletion mutations, 30 and primer misalignment may 1-1) . The region of the apoB gene predicted to contain the mutation, as determined by the size of the protein on the Western Wot, was amplified by polymerase chain reaction using primers and conditions described in "Methods." The DNA fragment was cloned Into pGEM-T, and clones containing the correct insert were identified as described. occur at polymerase pause sites. 31 To test whether this was feasible for the apoB-70.5 insertion mutation, primer extension reactions were carried out using the wild-type sequence as template, and the resulting products were analyzed on a denaturing poryacrylamide gel (Fig 4) . Using two different DNA polymerases, Sequenase 2.0 (a T7 DNA polymerase, Fig 4A) and AmpliTia( Taq polymerase, Fig 4B) , evidence of a polymerase pausing site was found near the end of the 7-adenine (A) repeat. A product of the correct size, indicated by the arrows in Fig 4 , accumulated over time, and this was reproduced in several separate experiments. The pausing of the enzymes, eg, as shown for Ampli7a^ (Fig 4A) , could be abolished by increased enzyme concentration, in agreement with published data. 32 Thus, the presence of a polymerase pause site appears to correlate with the site of the apoB-70.5 mutation.
Effect of ApoE and ApoB Genotypes on VLDL
/3-VLDL (as well as a-VLDL) bands were clearly evident in the whole plasmas, total VLDLs, and the VLDL1-3 subclasses of the proband (1-1) and the apoE2/E2-control (Fig 5) . A broad ^-migrating band was also present in the plasma of the proband's apoE2/E2 son (II-4), but a-and /3-VLDL were less well denned (results not shown). In contrast, only a-migrating and no /3-migrating particles were observed in the VLDLs of the apoB-75 control subject.
The proband and his son had identical and elevated VLDL-C/TG ratios (0.29) (Table 1) versus the apoB-75-apoE3/E4 control subject (0.12) but lower than the ratio of the apoE2/E2 control subject (0.40). The two unaffected members of the kindred (1-2 and H-l) with apoE2/E3 genotype had lower ratios (0.25 and 0.14). VLDLs from the proband also were enriched in cholesterol ester (0.14 mass fraction) ( Table 2 ) compared with the VLDL of the apoB-75 control subject (0.08 mass fraction), but enrichment was not as high as in the VLDL of the apoE2/E2 control subject (0.20 mass fraction). Conversely, the triglyceride mass in the proband's VLDL was less (0.51 mass fraction) than that of the apoB-75 control subject (0.57 mass fraction) but not as low as that of the apoE2/E2 control subject's VLDL (0.42 mass fraction).
VLDL apolipoprotein contents also were altered ( Table 2 ). Most striking were the high apoE/apoC ratios in the proband and the apoE2/E2 control subject (0.22) versus the apoB-75 control subject (0.1). When each of the three apolipoproteins E, B, and C were calculated as a fraction of the total apolipoproteins E+B+C, an enrichment in apoB and apoE was evident in the proband and the apoE2/E2 control subject compared with the apoB-75 control subject. Thus, the VLDLs of the proband and his son had electrophoretic migrations and lipid and apoprotein compositions characteristic of dysbetalipoproteinemia.
Llpoprotein Density Profiles
The DGUC cholesterol profile for the proband (Fig  6A), his son (Fig 6B) , the apoB-75 control subject ( Fig I -1, B70 E indicates apoE band quantified by densitometric scanning of the Coomassie-stained gel; B, apoB bands determined as for apoE; and C, apoC bands as for apoB and apoE, total apoC areas scanned. Triglyceride, cholesterol ester, free cholesterol, phosphollpids, and protein were determined as described in "Methods." Apolipoprotein (apo) E, B, and C in 50 /^g of very-low-density lipoprotein (VLDL) protein were quantified after separation on a 3% to 25% SDS-PAGE gel as described. The total amount of apoB was obtained by adding the areas of apoB-100, apoB-48, and the truncated apoB where applicable. Ratios were calculated as shown. 6B ) more closely resembled the profile of the apoE2/E2 control subject than the apoB-75 control subject in that there was a broader peak of VLDL and IDL density particles than that seen in the apoB-75 control subject. The fractional triglyceride and cholesterol distributions among the major lipoproteins in the apoE2/E2 subjects were shifted into the VLDL and IDL density ranges and away from LDL, which were less well-defined peaks and lower in quantity than was the case for the apoB-75 heterozygote and the normal control subject (Table 3) . ApoB-100 in the apoE2/E2 subjects exhibited a broad distribution ranging from VLDL to LDL. By contrast, the apoB-100 distribution profile for the apoB-75 control subject was more defined, with a clearer peak at LDL fractions 11 to 19, which accounted for 0.64 of the total apoB-100 in this control subject versus 0.46 for the proband.
ApoB-70.5 floated as one peak between fractions 11 to 17, accounting for 0. 22 served in both the proband and his son in a separate experiment. In contrast, apoB-75, a truncation of similar size to apoB-70.5, exhibited one major peak (fraction 19 to 25), accounting for 0.71 of total apoB-75 (Fig 6C) . Two fractions from the DGUC profiles of the proband and his son contained LDL populations of distinct sizes that could be separated by nondenaturing gradient gel electrophoresis (GGE) (see insets in Fig 6A and 6B) . The lower-density fraction was predominantly enriched in apoB-100 as determined from the immunoblots of the SDS-PAGE gels, whereas the higher-density peak contained predominantly apoB-70.5 (Fig 6A and 6B) . DGUC fractions 1, 3, 5, and 7 (d< 1.033 g/mL) were analyzed for apoB-100 and apoB-48 contents by SDS-PAGE and immunoblotting (Fig 7) . As expected, apoB-100 was present in each of the fractions of all four subjects, the apoB-70.5 truncation is present in the proband and his son, and the apoB-75 truncation in the apoB-75 control Table 1 for other abbreviations. Results are expressed as decimal fractions of the total summed gradient. VLDL and IDL represent elution fractions 1-10; LDL, fractions 11-24; and HDL, fractions 30-45 (see Fig 6) . subject Dark apoB-48 bands were present in the proband, his son, and the apoE2/E2 control subject. By contrast, apoB-48 was barely detectable in the fractions of the apoB-75 control subject. Ratios of apoB-48/apoB-100 in fraction 1 determined by scanning densitometry were 0.21, 0.15, and 030 for the apoE2/E2 control subject, the proband, and his son, respectively. The ratio for the apoB-75 control subject was <.O5. The redistribution of cholesterol apoB-100 toward VLDL and IDL fractions and away from LDL and the presence of excessive apoB-48 in VLDL-IDL density fractions are also characteristic of dysbetalipoproteinemia.
B75 Control
Lipoprotein Size (FPLC) Profiles
Plasma cholesterol eluted in three major peaks corresponding to VLDL, LDL, and high-density lipoprotein (HDL) ( Table 4 ). The apoB-75 control subject had a major peak of LDL cholesterol and a lesser peak of HDL cholesterol but very little VLDL and IDL cholesterol. By contrast, the proband and his son exhibited relatively large VLDL cholesterol peaks with broad shoulders on the LDL cholesterol peak corresponding to particles intermediate in size between VLDL and LDL similar to the apoE2/E2 control subject. The distribution of apoB-100 in the FPLC profiles was similar for the proband, his son, and the apoE2/E2 control subject and corresponded with the broad distribution of cholesterol in fractions VLDL and IDL at the expense of LDL. The distribution of apoB-100 in the apoB-75 control subject reflected the different distribution of cholesterol favoring LDL-sized particles.
The majority of apoB-70.5 was associated with particles smaller than apoB-100 LDL. These small LDLs accounted for 0.65 and 0.73 of the apoB-70.5 protein in the proband and his son, respectively. The remainder of the apoB-70.5 was distributed among particles of IDL to normal LDL in size making up 0.32 (proband) and 0.25 (proband's son) of the total apoB-70.5. By contrast, apoB-75 was primarily associated with particles smaller than normal LDL size (0.80 of total), and less than 0.20 was associated with particles of IDL to LDL size.
Discussion
Two gene variants are present in our kindred. The first is a mutation in the apoB gene that leads to a truncated form of apoB, apoB-70.5. The second is homozygosity for apoE2. All truncated forms of apoB described to date have been associated with hypobetalipoproteinemia, and apoE2 homozygosity is associated with dysbetalipoproteinemia. The presence of both gene variants allowed us to assess their combined effects on lipoprotein profiles.
An insertion of an A residue between cDNA position 9754 and 9760 inclusive (Fig 3) specifies a truncated apoB 70.5% of the full-length apoB-100 protein. Most truncated apoB proteins described to date 1 have been due to either deletion of one or a small number of base pairs or to nonsense mutations. ApoB-70.5 appears to be the first truncation due to insertion of a base.
The apoB-52 truncation 33 is due to a 5-bp deletion, the exact position of which is ambiguous. The mutation site includes a 5'-AAG-3' repeat sequence, and we suggested primer misalignment, perhaps due to primer slippage, 30 as a possible mechanism by which this mutation may have arisen. In apoB-70.5, the exact position of the one added A to 7 preexisting A's is also ambiguous, and the insertion mutation may also have arisen by primer misalignment. In our previous report, 33 we described that besides nonsense mutations, small deletion mutations constitute a significant proportion of mutations leading to truncated forms of apoB. The apoB-70.5 mutation is the first mutation among 25 mutations of the apoB gene leading to truncated apoBs. Others, too, have found the frequency of insertion mutations to be much lower that those of deletion mutations. 34 Primer misalignment intermediates have been proposed to act as substrates for mutagenesis, and polymerase pause sites have been found at the sites of small deletion or insertion mutations. 31 We found a pause in DNA synthesis, with two different enzymes, near the end of the run of 7 A's in the apoB-70.5 mutation site. This finding is compatible with the hypothesis that porymerase pausing may contribute to mutagenesis. However, other factors cannot be ruled out.
Linton et al 35 described the apoB-86 frame shift mutation that resulted from a single base deletion. That deletion yielded a sequence consisting of 8 consecutive A's. Interestingly, the frame shift could be corrected probably at the transcriptional level by the insertion of a ninth A. Our case differs in that an insertion at the gene level caused the frame shift, and we had no possibility of detecting any potential correcting mechanism because our subjects were simple heterozygotes.
The apoE2/E2 phenotype is associated with the dysbetalipoproteinemia in normolipidemic subjects as well as in patients with type III hyperlipidemia. 36 ' 37 The apoE2/E2 control subject used here was typical of patients with treated type III hyperlipidemia 3840 and served as an adequate comparison control for these studies. We used an apoB-75/apoB-100 heterozygote as a comparison for the apoB-70.5/apoB-100 heterozygotes since no apoB-70.5 subjects without the apoE2/E2 genotype were available. Our results clearly demonstrate that remnantlike lipoproteins do accumulate even in the hypobetalipoproteinemic state. This is based on evidence from electrophoresis (Fig 5) , DGUC (Fig 6  and Table 3 ), FPLC (Table 4) , the lipid and apoprotein compositions of VLDL (Table 2) , and the presence of apoB-48 in the triglyceride-rich fractions (Fig 7) . With each technique, the data resembled the VLDL fractions of the apoE2/E2 control subjects (and other reported subjects with hypobetalipoproteinemia) rather than that of the apoB-75 control subject. This demonstrates the potency of the apoE2/E2 genotype in altering the hypobetalipoproteinemia profile. Although not tested directly, we propose that the dysbetalipoproteinemia is due to the delayed clearance of apoE2-containing lipoproteins from plasma. The presence of large proportions of both apoB-100 and apoB-70.5 in the VLDL to IDL range suggests the particles containing both types of apoB experienced delayed clearance. We have also demonstrated delayed clearance of intestinal particles during the fat tolerance test in the proband and his son but not in other subjects with FHBL heterozygous for apoB truncation in the absence of apoE2 homozygosityv 41 Fat intolerance and the presence of excessive amounts of apoB-48 even in the fasted state (Fig 7) as in our subjects are both well-described features of apoE2 homozygosity. 42 To what extent are the apoE2 homozygosity and the apoB truncation contributing to low total and LDL cholesterol concentrations in our subjects? The apoE2/E2 genotype is consistently associated with an O^/L reduction in mean total plasma cholesterol concentrations in general populations, 7 and even in hypobetalipoproteinemic subjects, a small but significant reduction of apoB was noted in apoE2/E2 subjects compared with other apoE phenotypes. 43 The <5th percentile total and LDL cholesterol levels and the =30% of normal apoB levels in our proband and his son are much lower than those seen in apoE2 homozygotes without any truncations of apoB but not significantly different from the very low mean total plasma or LDL cholesterol and apoB concentrations of our FHBL populations with truncated apoBs who are not apoE2 homozygotes. 2   -612   -17   -29 - 33 Thus, the apoB-70.5 mutation appears to be the major determinant of the low plasma cholesterol and apoB concentrations, whereas the apoE2/E2 genotype results in the presence of lipoprotein populations characteristic of dysbetalipoproteinemia.
